Phaseline

Companies › Immunocore

Immunocore: clinical trials, targets and expected readouts

4 active drug programs in 17 registered trials: 7 Phase 2, 6 Phase 1, 4 Phase 3; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Brenetafusp (IMC-F106C)
Immune-mobilizing monoclonal T cell receptor (ImmTAC) targeting PRAME-positive cancer cell
PRAMEPhase 3Advanced Melanoma; Select Advanced Solid TumorsOct 2027
Tebentafusp
Melanocyte protein PMEL binding agent
PMELPhase 3Advanced Melanoma; Uveal Melanoma; Melanoma (Skin); Locally Advanced Unresectable Uveal Melanoma …Mar 2028
IMC-R117C
PIWIL1 × CD3 bispecific ImmTAC protein
PIWIL1, CD3EPhase 1CancerNov 2026
IMC-P115C
Half-life extended (HLE) ImmTAC targeting PRAME; engages T cells to recognize PRAME-presen
PRAMEPhase 1PRAME PositiveSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06840119IMC-R117CPhase 1CancerOncologyNov 2026
NCT05315258TebentafuspPhase 2Melanoma (Skin)OncologyDec 2026
NCT06414590TebentafuspPhase 2Locally Advanced Unresectable Uveal MelanomaOncologyAug 2027
NCT07063875TebentafuspPhase 1Uveal MelanomaOncologySep 2027
NCT07156136IMC-P115CPhase 1PRAME PositiveOncologySep 2027
NCT06112314Brenetafusp (IMC-F106C)Phase 3Advanced MelanomaOncologyOct 2027
NCT07203391TebentafuspPhase 1Uveal Melanoma, MetastaticOncologyDec 2027
NCT04262466Brenetafusp (IMC-F106C)Phase 1Select Advanced Solid TumorsOncologyDec 2027
NCT07057596TebentafuspPhase 2Mestastatic Uveal MelanomaOncologyDec 2027
NCT06627244TebentafuspPhase 2Metastatic Uveal MelanomaOncologyFeb 2028
NCT05549297TebentafuspPhase 3Advanced MelanomaOncologyMar 2028
NCT05549297TebentafuspPhase 3Advanced MelanomaOncologyMar 2028
NCT06070012TebentafuspPhase 2Uveal MelanomaOncologySep 2028
NCT06942442TebentafuspPhase 2HLA-A*0201 Positive Cells PresentOncologyOct 2030
NCT06626516TebentafuspPhase 1Metastatic Uveal MelanomaOncologyOct 2030
NCT07276386TebentafuspPhase 2Metastatic Uveal MelanomaOncologyDec 2030
NCT06246149TebentafuspPhase 3Uveal MelanomaOncologyNov 2032

From the company's SEC filings

Cash and short-term investments of $901m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PRAME (2) PMEL (1) PIWIL1 (1) CD3E (1)

Companies with the same targets

Johnson & Johnson (Janssen) Regeneron Pharmaceuticals Amgen Roche AstraZeneca Neowise Biotechnology PDC*line Pharma SAS Immatics US Tiziana Life Sciences Sanofi

Companies built like this

Genmab Exelixis Sellas Life Sciences Group Immatics US Erasca

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.